Skip to content
EmergingResearch compoundReference only

Unifiram

Ampakine (DM-232), alkynyl variant of Sunifiram, AMPA-PAM.

NootropicNootropicampakineglutamateGlutamateAcetylcholine

Pharmacology

ClassNootropic · ampakine · glutamate
Primary targetAMPA receptors (ampakine-like enhancement)
Targets3 receptor targets
EvidenceReference only
Affected systemsGlutamateAcetylcholine

Contents

Related comparisons

Sunifiram vs Unifiram

WHAT IS UNIFIRAM?

Detailed overview

Unifiram (DM-232) is a designed alkynyl analog of Sunifiram (DM-235), with similar sub-mg in vivo activity in rat anti-amnestic models. Interestingly it does NOT directly act as an AMPA-PAM (unlike classical ampakines) – instead it improves glutamatergic signal-processing efficiency, enhancing how memory circuits respond to glutamate. Indirect activation at the NMDA glycine site + acetylcholine release modulation in cerebral cortex. Long-lasting hippocampal LTP elevation. Less activating than Sunifiram, more pro-cognitive profile; data report no adverse effects in studied models. No human data exist.

Mechanism

AMPA-PAM (Sunifiram-like)

Half-life

No human data

Legal status

Investigational, not approved

Receptor profile

  • AMPA receptorsStrong
  • Hippocampal excitatory transmissionStrong
  • Cholinergic systemModerate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No human safety data, only preclinical (rodent) and anecdotal reports
  • Anxiety, tension and restlessness (highly individual response)
  • Stimulating, energizing effect that can tip into overstimulation at higher doses
  • Possible sleep disruption if taken late in the day (stimulant-like profile)
  • Headache or agitation theoretically arising from glutamatergic (AMPA/NMDA) modulation
  • Unknown long-term safety, unknown tolerance and risk profile

Contraindications · 5

  • Pregnancy and breastfeeding: strictly avoid due to lack of human data
  • Caution with anxiety disorders or panic tendency (the stimulating effect may worsen them)
  • Epilepsy or seizure-threshold disorders: glutamatergic excitation may theoretically raise seizure risk
  • Combined with other stimulants or caffeine, increased agitation and anxiety are possible
  • Experimental, nowhere-approved substance; no established safe dosing or drug-interaction profile

Related Nootropics

Same therapeutic category

FAQ

FAQ

Unifiram is an experimental, lab-designed compound developed as a relative of the nootropic Sunifiram, and it showed memory-enhancing effects at very low doses in animal studies. Importantly, there is essentially no human research on it, so this is a purely research-stage substance with very little data on its real-world effects or safety in people.

Telegram

Have a question about Unifiram?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC13H15FN2O3S
UpdatedJune 19, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.